Enzyme-Linked Immunosorbent Assays Using Novel Japanese Encephalitis Virus Antigen Improve the Accuracy of Clinical Diagnosis of Flavivirus Infections

Graduate Institute of Veterinary Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan, Republic of China.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.47). 06/2008; 15(5):825-35. DOI: 10.1128/CVI.00004-08
Source: PubMed


The cross-reactive antibodies induced by flavivirus infections confound serodiagnosis and pathogenesis, especially in secondary infections caused by antigenically closely related yet distinct flaviviruses. The envelope (E) glycoprotein fusion peptide contains immunodominant cross-reactive determinants. Using a recombinant Japanese encephalitis virus (JEV) premembrane and E expression plasmid producing JEV virus-like particles (VLPs), dramatic reductions in cross-reactivity were produced by the G106K-L107D (KD) double-mutant VLP against a panel of flavivirus murine monoclonal antibodies. Human serum panels from patients with recent flavivirus infections were analyzed to compare the accuracy of JEV wild-type (WT) and KD VLPs as serodiagnostic antigens in enzyme-linked immunosorbent assays. Statistical analysis demonstrated significant differences in assay performances for accurate determination of current JEV infections between WT and KD antigens by detecting immunoglobulin M antibodies at a serum dilution of 1:4,000 (likelihood ratios = 2.74 [WT] and 22 [KD]). The application and continued development of cross-reactivity-reduced antigens should improve both flavivirus infection serodiagnosis and estimates of disease burden.

Download full-text


Available from: Li-Kuang Chen, Jun 18, 2014
  • Source
    • "But, at the same time, various virus resistant neutralization antibodies may circulate in the blood stream, even then virus escapes the immune defense [29]. Therefore, mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein is highly essential and important to improve the accuracy of clinical diagnosis of flavivirus infections [52]. Thus, mutations generated in virus genome not only affect epitope conformational structure in antigenic binding region of protein but also affect protein folding [53]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: paper highlights various reasons of evolution of new mutants/variants of JE virus and its effects on neurovirulence, antigenicity, host immune responses, and disease transmission in endemic areas. Virus is reorganizing its genome by making sequence alterations, single site mutations, cluster specific reversions, and amino acid substitutions in neutralizing antigenic sites mainly in N í®í° glycosylation sites and epitopic regions of S and E proteins. Virus is regularly changing gene order, gene density by making substitution point mutations in important structural genes which make virus envelope proteins. Further, JE virus acquiring new genetic variations and adaptabilities through genetic recombination of wild strains with vaccine strains and assimilating new lethal genes that lead to emergence of molecular variants/mutants. These newly emerged JE virus genotypes have attained the ability to escape the immune defense and show wider resistance against vaccines and therapeutic agents. Thus new strains did significant elevation in the level of neurovirulence, antigenicity and pathogenesis. It is causing very high mortalities in various infant groups and imposing lifelong irreversible disorders in survivors and showing a regular trend of emergence and reemergence in endemic areas. The present review article emphasizes methods to suppress virus replication, reversion of neurovirulence, attenuation and an utmost need of more potential vaccines against cross reactive heterologous genotypes of JE virus to control disease transmission and mortalities occurring in endemic areas.
    01/2014; 2014(5). DOI:10.1155/2014/516904
  • Source
    • "Also, PL10 could successfully distinguish DENV serotypes from other flaviviruses in immunized mice sera. The high degree of antibody cross-reactivity among different flaviviruses has been a diagnostic challenge to distinguish various flaviviral infections, and this limitation is apparent for members of DENV serotypes [57,58]. It has been previously reported that prM-specific antibodies could be applied as a diagnostic marker to distinguish previous infection of DENV from JEV [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dengue virus (DENV) infection is the most important arthropod- borne viral disease in human, but antiviral therapy and approved vaccines remain unavailable due to antibody-dependent enhancement (ADE) phenomenon. Many studies showed that pre-membrane (prM)-specific antibodies do not efficiently neutralize DENV infection but potently promote ADE infection. However, most of the binding epitopes of these antibodies remain unknown. In the present study, we characterized a DENV cross-reactive monoclonal antibody (mAb), 4D10, that neutralized poorly but potently enhanced infection of four standard DENV serotypes and immature DENV (imDENV) over a broad range of concentration. In addition, the epitope of 4D10 was successfully mapped to amino acid residues 14 to18 of DENV1-4 prM protein using a phage-displayed peptide library and comprehensive bioinformatics analysis. We found that the epitope was DENV serocomplex cross-reactive and showed to be highly immunogenic in Balb/c mice. Furthermore, antibody against epitope peptide PL10, like 4D10, showed broad cross-reactivity and weak neutralizing activtity with four standard DENV serotypes and imDENV but significantly promoted ADE infection. These results suggested 4D10 and anti-PL10 sera were infection-enhancing antibodies and PL10 was infection-enhancing epitope. We mapped the epitope of 4D10 to amino acid residues 14 to18 of DENV1-4 prM and found that this epitope was infection-enhancing. These findings may provide significant implications for future vaccine design and facilitate understanding the pathogenesis of DENV infection.
    BMC Microbiology 08/2013; 13(1):194. DOI:10.1186/1471-2180-13-194 · 2.73 Impact Factor
  • Source
    • "In contrast, a significant fraction of E protein-specific B cells appear to produce antibodies specific for the E-DII-FL (Throsby et al., 2006), and antibodies against this determinant are readily detected in serum. Using a similar approach, mutations in the fusion loop have improved the accuracy of serum diagnostic assays for DENV, JEV, and SLEV by eliminating detection of the highly crossreactive fusion loop antibodies (Chiou et al., 2008, and references within). As a more detailed understanding of the structural basis of antibody recognition and neutralization of flaviviruses emerges, it may be possible to generate highthroughput epitope-based diagnostic assays with a series of E protein variants that defines serotype specificity and functional classes of neutralizing antibodies after infection or vaccination. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Flaviviruses are a group of small RNA viruses that cause severe disease in humans worldwide and are the target of several vaccine development programs. A primary goal of these efforts is to elicit a protective humoral response directed against the envelope proteins arrayed on the surface of the flavivirus virion. Advances in the structural biology of these viruses has catalyzed rapid progress toward understanding the complexity of the flavivirus immunogen and the molecular basis of antibody-mediated neutralization. These insights have identified factors that govern the potency of neutralizing antibodies and will inform the design and evaluation of novel vaccines.
    Cell host & microbe 10/2008; 4(3):229-38. DOI:10.1016/j.chom.2008.08.004 · 12.33 Impact Factor
Show more